Adaptimmune Therapeutics ADAP reported its Q1 earnings results on Friday, May 12, 2023 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Adaptimmune Therapeutics missed estimated earnings by 100.0%, reporting an EPS of $0.0 versus an estimate of $-0.14.
Revenue was up $44.03 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.07 which was followed by a 5.3% drop in the share price the next day.
Here's a look at Adaptimmune Therapeutics's past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.25 | -0.24 | -0.25 | -0.22 |
| EPS Actual | -0.18 | -0.24 | -0.28 | -0.32 |
| Revenue Estimate | 4.12M | 4.04M | 6.00M | 3.29M |
| Revenue Actual | 11.03M | 7.01M | 5.54M | 3.58M |
To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
